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Abstract 
Polyoxidonium (PO) has been recognized as an effective, safe immunomodulator with a marked immuno-
stimulating activity suitable for the complex treatment of both acute and chronic infections in humans. 
The PO contains high-polymeric units of 100 kDa based on both N-oxide 1,4- ethylene piperazine  and 
(N-carboxyethyl-) 1,4 ethylene piperazine bromide. Recently, PO has been licensed for human use in the 
new Russian trivalent polymeric subunit flu vaccine "Grippol." This will open a possibility of using the 
PO for the development of vaccines against other infectious diseases. Here we studied the potency of the 
PO in eliciting the humoral immune response to specific antigens of Chlamydia spp. (C1 and C2) and 
Yersinia pestis (Pla, LcrV, and YopM) in comparison with the Freund's complete (FCA) and Titermax 
(TMC) adjuvants. The Balb/c mice were primed with a single intraperitoneal injection of the 10-20 µg of 
antigen mixed 1:1 with either adjuvant and boosted 3 times with the same antigen alone. We found at 
least 8- to 16-fold and 4- to 8-fold increases in IgG titers to Chlamydia and Yersinia antigens, 
respectively, after injections of the antigens with the PO in relation to the use of the either FCA or TMC. 
The PO was found to be absolutely safe for animal health, since there were no visible adverse reactions at 
the inoculation site characteristic of those seen with the other adjuvants, in particular FCA. Thus, the PO 
could be the adjuvant of choice to elicit a strong immune response to the major antigens of Chlamydia 
and Yersinia, suggesting the possibility of its use in developing bi- and tri-valent subunit vaccines with 
enhanced immunity. The exact mechanism of priming the immune response by the PO is under 
investigation.   
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1. Main text  
Chlamydia trachomatis is the most prevalent causative agent of sexually transmitted bacterial 
infections of the genital tract worldwide [1]. Being asymptomatic in more than 70% of all cases, 
chlamydial infection can often lead to severe reproductive sequelae, including pelvic inflammatory 
disease, ectopic pregnancy and infertility [1, 2]. Therefore, the development of an effective vaccine to 
control Chlamydia infection is an immediate priority. A number of specific Chlamydia antigens, including 
the major outer membrane protein MOMP, were reported to have suitable immunogenic and protective 
properties and are considered to be prospective candidates for the construction of subunit vaccines. 
Various vaccine and adjuvant formulations have been tested experimentally in animal models. 
Unfortunately, there is no chlamydial vaccine available, and this deficiency may be, in part, due to the 
absence of a high effective immunomodulator suitable for human use. A number of commonly used 
adjuvants, such as Freund's complete (FCA), Titermax (TMC), CpG ODN, etc. are acceptable for animal 
models only, but are not licensed for humans. 
Yersinia pestis, a causative agent of plague, is historically responsible for more than 200 million human 
death cases. Additionally, WHO reports about 2000 incidents of plague annually worldwide. To address 
this, a new generation of subunit plague vaccine candidates containing a combination of protective Y. 
pestis antigens has been tested in various animal models. However, these vaccines have been formulated 
with the alhydrogel, an adjuvant approved for human use in Western countries [5, 6]. However, to 
improve the efficacy of plague subunit vaccines, a more potent immunomodulator is needed. 
Polyoxidonium (PO) is a novel synthetic polymeric adjuvant [4] with low toxicity that has been licensed 
for human use in the new Russian trivalent polymeric subunit flu vaccine "Grippol." PO can be potentially 
used as an adjuvant for induction of a rapid and enhanced immune response to Chlamydia and Yersinia 
antigens. 
The aim of our study was to investigate the potency of PO in eliciting a humoral immune response to 
specific antigens of Chlamydia spp. (C1 and C2) and Y. pestis (Pla, LcrV, and YopM) in Balb/c mice. 
1.1. Methods 
To elicit an immune response to Chlamydia, Balb/c mice (n=3 in each of the group) were immunized 
intraperitoneally with equal doses of specific chlamydial antigens C1 and C2 mixed with either the PO, 
TMC or the FCA. Here, we used three immunization schedules, namely accelerated (A), median (M) and 
routine (R). Each group of animals were primed with a single intraperitoneal injection of the 10-20 µg of 
antigen mixed 1:1 with either adjuvant and boosted 3 times with the same antigen alone. Time interval 
between repeated injections was 3 days (schedule A), 14 days (schedule M), and 21 days (schedule R).  
In a parallel experiment, Balb/c mice were inoculated with recombinant Y. pestis antigens, such as Pla, 
LcrV, or YopM by using similar protocols. In this case, only accelerated (A) and routine (R) 
immunization schedules were used. On day 4 after the last immunization, each mouse was bled, and 
pooled group sera were analyzed by ELISA for the presence of specific antibodies.  
1.2. Results 
To test the safety of various adjuvants, the manifestation of the inoculation site, as well as general 
animal health conditions were carefully monitored.  After the first injection of either Chlamydia or 
Yersinia antigens in the FCA, we observed several side effects, such as perspiration, reduction in 
mobility, inflammation and formation of a small nodule at the inoculation site (Fig. 1). 
In contrast to the FCA, the PO is water-soluble and was easily mixed with the antigens. A subsequent 
inoculation of the antigens emulsified in the PO resulted in the absence of notable complications at the 
administration site (Fig. 2). No signs of pain, perspiration, depression in activity or emotional stress were 
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observed, when each animal was carefully examined. Thus, the PO appeared to be less harmful in 
comparison with the FCA in a mouse model (Table 1). 
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Fig. 1. The appearance of a small nodule at the inoculation site subsequent to the injection of C1 (A) and Pla (B) 
emulsified with the FCA. 
 
  A                                                        B 
   
 
 
 
 
 
 
 
 
 
 
Fig. 2. The lack of adverse reactions at the inoculation site in mouse inoculated with C1 (A) and Pla (B) mixed with 
the PO. 
 
Table 1. Comparative side-effect features of PO and FCA in a mouse model of immunization 
Reactions observed after treatment with 
PO FCA 
Antigens used 
Activity 
depression 
Pain 
response 
Granuloma 
formation 
Activity 
depression 
Pain 
response 
Granuloma 
formation 
C1 - - - + + + 
C2 - - - + + + 
Pla - - - + + + 
LcrV - - - + + + 
YopM - - - + + + 
 
 To compare the effect of the PO and the FCA in eliciting the specific chlamydia antibodies, the IgG 
titers to the C1-C2 antigens were measured in the murine sera by using three immunization schedules in 
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parallel. It was found that the PO considerably out-performed the FCA when the accelerated schedule A 
(i.e., a shortened immunization period) was applied. When the PO was utilized, the antibody titers to C1-
C2 were increased by 8- to-16-fold in comparison with those seen following FCA usage. The median (M) 
immunization schedule generally produced reduced IgG titers when compared to titer values in other 
schemes. Nevertheless, we observed about a 4-fold increase in titers to chlamydial antigens in the group 
of mice inoculated with PO. No significant difference in antibody levels was found in the groups of mice 
treated with either PO or FCA when the longer schedule R was applied (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Comparative ELISA antibody titers detected in Balb/c mice immunized with C1-C2 mixed with either the PO 
or the FCA using three different immunization schedules. 
 
 Immunization of Balb/c mice with Y. pestis antigens produced results similar to those obtained for 
Chlamydia antigens. Table 2 illustrates specific antibody titers to Pla obtained with the use of the three 
adjuvants tested. Antibody titers to Pla elicited with PO were comparable to those induced with TMC. 
 
Table 2. Comparative antibody titers to Pla in BALB/c mice immunized with different adjuvants (schedule A) 
 
Adjuvant PO TMC FCA 
Antibody titers in ELISA 1:12 800 1:6 400 – 1:12 800 1:200 – 1:400 
 
 The use of PO with other two antigens of Y. pestis (LcrV and YopM) resulted in high antibody titers to 
these antigens (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. ELISA antibody titers detected in Balb/c mice immunized with either LcrV or YopM mixed with PO using 
accelerated immunization schedule A. 
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 High levels of immune response to Y. pestis antigens were observed in FCA-treated mice only when a 
long-lasting immunization schedule R was used (Table 3), which was similar to the results obtained with 
Chlamydia antigens. 
 
Table 3. Antibody titers to Y. pestis antigens in BALB/c mice immunized with FCA (schedule R) 
 
Antibody titers to Adjuvant 
Pla LcrV YopM 
FCA 1:25 600 – 1: 102 400 1:102 400 – 1:409 600 1:51 200 – 1:409 600 
1.3. Conclusions 
1. The novel polymeric adjuvant PO was found to be less reactogenic than FCA and could be 
considered as the adjuvant of choice in animal studies.  
2. The use of PO allowed us to obtain a high level of specific antibodies to either Chlamydia or Y. 
pestis antigens in a murine model. 
3.  PO could shorten significantly the immunization time of Balb/c mice with Chlamydia & Y. 
pestis antigens, while eliciting high titers of the specific antibodies. 
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